“Global Respiratory Inhalers market set to grow to $38bn by 2023” says new Visiongain report

24 October 2018
Pharma

Visiongain has launched a new pharma report: The Global Respiratory Inhalers Market 2018-2028: Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.

Respiratory inhalers are used to relieve the symptoms of asthma and COPD and prevent exacerbations, which can lead to expensive hospital stays for patients and increase the risk of mortality. The increase in emission of air pollutants due to economic and industrial growth has made air quality an environmental problem of first order in many European and North American countries and it is now a growing problem in other parts of the world. Air pollution is convincingly associated with many signs of asthma aggravation. On the other hand, the prevalence of COPD is largely attributed to an increase in tobacco use, air pollution, and is also linked to the world’s ageing population, as the prevalence and morality of COPD increase with age. Thus, growing burden of respiratory diseases is likely to propel the growth of respiratory inhalers market.

The lead analyst of the report commented "The market is maturing with the launch of generic products expected during the forecast period. The launch of advanced products such as triple combination therapy and focus on development of e-devices are expected to drive the market growth. The emergence of connected devices - including inhalers, wearable sensors and mobile apps presents new growth opportunities."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., GlaxoSmithKline (GSK), Merck & Co., Novartis, Teva.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever